Compare ACADIA Pharmaceuticals Inc. (ACAD) vs HP Inc (HPQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs HP Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while HP Inc trades at $23.66 (market cap $21.00B). The key difference: HP Inc is far larger — about 4.7× ACADIA Pharmaceuticals Inc.'s market cap, and HP Inc pays a 5.23% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | HPQ | |
|---|---|---|
Market Cap | $4.49B | $21.00B |
Sector | Health | Technology |
52-Week High | $28.06 | $29.35 |
52-Week Low | $20.06 | $18.20 |
Enterprise Value | $3.69B | $28.16B |
Dividend Yield | — | 5.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
HPQ trades at $22.96, up 4.7% today, with strong earnings momentum as it has beaten EPS estimates for three consecutive quarters. The stock shows attractive valuation metrics with a P/E of 8.37 and P/S of 0.37, while technical indicators signal bearish momentum despite oversold RSI conditions. Recent developments include strategic AI partnerships with OpenAI and Ferrari, positioning the company for potential growth in the AI PC market.
The outlook remains cautiously optimistic with analyst consensus at $22.00, slightly below current price. Key opportunities include AI PC adoption and margin expansion, while risks involve competitive pressures and declining profit margins. Institutional sentiment leans neutral with 55% hold ratings, suggesting balanced risk-reward for value-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →
